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Background:  Coeliac  disease  is  a chronic  enteropathy  characterized  by an increased  mortality  caused  by
its complications,  mainly  refractory  coeliac  disease,  small  bowel  carcinoma  and abdominal  lymphoma.
Aim  of the  study  was  to  study  the  epidemiology  of  complications  in  patients  with coeliac  disease.
Methods:  Retrospective  multicenter  case–control  study  based  on collection  of  clinical  and  laboratory
data.  The  incidence  of  complicated  coeliac  disease  was  studied  among  coeliac  patients  directly  diag-
nosed  in  four  Italian  centres.  Patients  referred  to these  centres  after  a diagnosis  of coeliac  disease  and/or
complicated  coeliac  disease  in other  hospitals  were  therefore  excluded.
Results:  Between  1/1999  and  10/2011,  1840  adult  coeliac  patients  were  followed  up for 7364.3  person-
years.  Fourteen  developed  complications.  Since  ﬁve  patients  died,  at  the  end  of  the observation  period
(10/2011),  the  prevalence  of  complicated  coeliac  disease  was  9/1835  (1/204,  0.49%, 95%  CI  0.2–0.9%).  The
annual  incidence  of  complicated  coeliac  disease  in the  study  period  was  14/7364  (0.2%,  95%  CI  0.1–0.31%).
Although  complications  tend  to occur  soon  after  the  diagnosis  of coeliac  disease,  Kaplan–Meier  curve
analysis  showed  that  they  can  actually  occur  at  any  time  after  the  diagnosis  of coeliac  disease.
Conclusions:  Complications  of  coeliac  disease  in our cohort  were  quite  rare, though  characterised  by a
very  high  mortality.
©  2013  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All rights  reserved.
1. Introduction
Coeliac disease (CD), a chronic enteropathy due, in genetically
predisposed individuals, to the intake of gluten, is well known as
being characterized by both a high prevalence and an increased
mortality [1,2]. Although in the great majority of patients the prog-
nosis of this disease is excellent, and most coeliac patients die
for causes unrelated to CD, some of these patients may  develop
a series of serious complications, such as refractory CD type 1 and
type 2 (RCD1 and RCD2), ulcerative jejunoileitis (UJI), enteropathy-
associated T-cell lymphoma (EATL), abdominal B cell lymphoma
(ABL), and small bowel carcinoma (SBC), which dramatically reduce
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the prognosis [3–7]. In particular, the ﬁve-year survival rate is
between 80% and 96% in patients with RCD1, between 40% and 58%
in patients with RCD2 and drops to less than 20% in patients with
CD complicated by EATL [8–13].
The ﬁrst papers on the molecular diagnosis of complicated CD
(CCD) were published more than 10 years ago [14], and since then
several papers were published on this subject [4–19]. Despite these
achievements, the literature still provides only minor and insufﬁ-
cient indications on the incidence of these conditions in patients
with CD [8,15–19]. The reason for this lack of data can probably
be attributed to the fact that most patients with CCD are sent to
large referral centres. Similarly, a considerable number of patients
with non-complicated CD are also referred to these centres. While
sending all these patients to such referral centres certainly makes it
easier to study the disease, it also introduces an inevitable selection
bias and thus makes an epidemiological study of CCD extremely
difﬁcult.
Our aim was to resolve this bias by studying how many patients
with CD diagnosed directly in a single centre subsequently develop
a complicated form of CD.
1590-8658/$36.00 © 2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
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2. Patients and methods
A retrospective multicenter case–control study based on collec-
tion of clinical and laboratory data was carried out in four Italian
referral centres for the study of CD and its complications. In each
of these centres it was calculated how many patients with CD were
diagnosed directly in the centre between January 1999 and October
2011. The patients were diagnosed on the basis of a duodenal biopsy
showing a certain degree of villous atrophy and of positive anti-
transglutaminase/antiendomysial antibodies. This means that all
patients with CD that were seen at the centre to obtain a certiﬁcate
entitling them to gluten-free products through the Italian National
Health Service, for conﬁrmation of a diagnosis made elsewhere
or for suspected CCD, were excluded. Among all the remaining
patients, those whose malabsorption symptoms persisted despite
at least 12 months of a gluten-free diet and in whom a diagno-
sis of complicated CD was made were selected. More speciﬁcally,
the diagnosis of RCD2 was based on a ﬂat duodenal mucosa not
responding to 12 months on a gluten-free diet and evidence of
an aberrant intraepithelial lymphocyte population and/or gamma
chain T cell monoclonal rearrangement; diagnosis of RCD1 was
based on a ﬂat duodenal mucosa not responding to 12 months
on a gluten-free diet but without the diagnostic criteria for RCD2;
ﬁnally, the diagnoses of EATL, ABL, UJI, and SBC were based on
morphological criteria [9–12]. For all these patients, the follow-
ing information was collected: sex, date of birth, date of diagnosis
of CD, date of the last examination at the centre, date of diagnosis
of complications of CD, if applicable, and date of death, if applica-
ble. In this article, the term “cases” indicates patients with CD who
subsequent developed a complication while the term “controls”
indicates patients with CD who did not subsequently develop a
complication.
The study was approved by the ethics committee of the Fon-
dazione IRCCS Policlinico San Matteo.
3. Statistics
The incidence of complication was evaluated both on the whole
patient population and on the subsets from each of the four referral
Centres. Differences of incidence were analysed with 2 × K con-
tingency tables, applying Fisher’s exact test in cases of too small
numbers [19]. The 95% conﬁdence intervals were calculated accord-
ing to Poisson’s exact test.
Curves of duration of follow-up and complication-free survival
were calculated according to the Kaplan–Meier technique and,
when applicable, differences were analysed with the log-rank test
[20,21].
The complication-free survival was further analysed through
univariate and bivariate regressions applied to the proportional
hazards model [22], with sex and age at diagnosis of CD as covari-
ates. The relative risk, related to the adequacy of the model and
calculated per single measurement unit of the covariate, was
derived from the natural exponential of the partial regression coef-
ﬁcient.
The analyses were performed using the Stat View 5.0 software
package (Abacus Concepts, Berkeley, California, 1995) for Macin-
tosh.
4. Results
Between January 1999 and October 2011, a total of 2071 adult
patients with CD were diagnosed in the four centres participating in
the study. Two-hundred and thirty-one of them were not seen after
the initial diagnosis of CD and were considered to be lost to follow-
up. The remaining 1840 (1390 F, mean age 37.0 years ± 11.9) had a
Fig. 1. Kaplan–Meier curve showing the complication-free survival in patients with
coeliac disease. The onset of complications is a rare event but can occur even many
years after the diagnosis of coeliac disease.
cumulative follow-up of 7364.3 person-years (mean follow-up 48.0
months, 95% CI 0.03–160.5). During this period, 14 of these 1840
patients developed a CD-related complication (11 F, mean age at
diagnosis of CCD 61.1 years ± 12.2; 5 cases of RCD1, 3 SBC, 2 RCD2,
2UJI, 1 EATL, 1 ABL). All 14 had severe malabsorption symptoms
and 5 of them died (3 F, mean age at death 69.6 years ± 8.2; 3 cases
of RCD1, 1 EATL, 1 SBC). Since none of the 1826 controls (1379 F,
mean age at diagnosis of CD 35.4 years ± 11.4) died, at the end of
the observation period (October 2011), the prevalence of CCD in
our population of patients with CD was therefore 9/1835 (1/204,
0.49%, 95% CI 0.2–0.9%). The annual incidence of CCD in our study
period was 1/526.3 (0.2%, 95% CI 0.1–0.31%).
Fig. 1 shows the Kaplan–Meier curve for complication-free
cumulative survival. This analysis conﬁrms that the onset of com-
plications is fortunately a rare event that can, however, also occur
many years after the diagnosis of CD.
Age at diagnosis of CD in the cases was signiﬁcantly higher
compared with age at diagnosis of CD in the controls (59.2 ± 12.2
years vs. 36.8 ± 12.4; p < 0.0001). Fig. 2 shows that a value of age at
diagnosis of CD between the two means (48 years) discriminates
the complication-free survival very well. The analysis according
to the proportional risks model shows that the age at diagnosis
Fig. 2. Complication-free survival according to age at diagnosis of coeliac disease.
Thick line > 48 years; thin line ≤ 48 years.
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Table  1
Bivariate analysis of the complication-free survival according to the proportional
hazards model showing that age at diagnosis of coeliac disease is closely correlated
with complication-free survival, whereas sex is not.
Coefﬁcient Chi-square p
Age 0.053 28.s666 <0.0001
Sex  −0.300 0.245 0.62
Fig. 3. The thick central line shows the estimated risk of complications on the basis
of  age at diagnosis of coeliac disease; the thin external lines show the 95% conﬁ-
dence interval. Age at diagnosis of coeliac disease is linked to an increased risk of
complicated coeliac disease, though not patient age.
of CD, unlike sex, is closely related with complication-free sur-
vival (Table 1). The close correlation between the age and the
complication-free survival made it possible to assess the relative
hazard of complication. Fig. 3 shows the estimated complication
risk based on age at diagnosis of CD.
5. Discussion
Although it has been known for many years that the increased
mortality in CD is due to its feared complications [23], the litera-
ture reports very few epidemiological data on these complications
[8,15–19]. This lack of data can undoubtedly be attributed both to
the signiﬁcant selection biases in these series of patients and to the
difﬁculties caused by the lack of uniform diagnostic criteria for the
various forms of CCD [15,16].
Our study is the ﬁrst to evaluate the incidence of CCD in
patients with CD. This was a multicentre study involving almost
2000 patients from four CD centres distributed throughout Italy.
Although we  took into account only coeliac patients directly
diagnosed in our centres and excluded those patients diagnosed
elsewhere and then referred to us, our results could overestimate
the risk of complications. Despite this, our results show that the
complications of CD are rare but that they can occur even many
years after the diagnosis of CD and conﬁrm that these complica-
tions have a high mortality rate [2,8–13]. Since we  did not record
any death from other causes among either cases or controls (this
means none of them died from cardiovascular disease, infections,
any type of cancer, respiratory disease etc.), our results reﬂect the
speciﬁc mortality of coeliac patients due to CCD itself. Finally, we
recorded only 14 cases of complications, so it was obviously not
possible to study the epidemiology of the various forms of CCD.
RCD was the most common form of CCD (50% of the cases).
It has been known for some time that the risk of complica-
tions in patients with CD is linked to a series of factors such as
age at diagnosis of CD, the diagnostic delay of CD, the strictness
of the gluten-free diet, the clinical form of CD and the homozygos-
ity for DQ2 [2,18,23–26]. Our results conﬁrmed a strong correlation
between age at diagnosis of CD and the risk of developing a compli-
cated form of CD. Fig. 3 does in fact show that the risk of developing
complications increases logarithmically with the increase in age.
On the other hand, we  could not conﬁrm the recently shown
correlation between sex and risk of developing CCD [18]. The ret-
rospective and multicentre nature of this study, carried out over a
period of almost 13 years, did not allow us to study a correlation
with other parameters such as the strictness of gluten-free diet, the
clinical form of CD and the homozygosity for DQ2.
Due to its retrospective nature, our study was hindered by
inevitable difﬁculties in data collection and thus by the inevitable
controls lost to follow-up. Since we  cannot exclude the possibility
that at least some of these controls were lost to follow-up pre-
cisely because they developed a complication, we must consider
that our results may  underestimate the true situation. On the other
hand, we noted that the vast majority of coeliac patients lost to
follow-up were all enrolled in one centre where histological recov-
ery of the duodenal mucosa while on a GFD is not routinely checked.
We therefore compared the results of this single centre with the
results of the other three centres grouped together. No signiﬁcant
difference emerged (data not shown).
All these problems could be resolved by a prospective study.
However, our results show that it would be necessary to enrol a
very large number of coeliac patients (>1000) who must be carefully
followed for at least 10–15 years in order to record the onset of any
complications. We  therefore believe that organizing such a study
would be extremely difﬁcult.
We conclude the complications of CD are very serious condi-
tions that can occur many years after the initial diagnosis of CD.
There is a strong correlation between risk of complication and age
at diagnosis of CD. Fortunately, these complications are quite rare.
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